iBio, Inc.IBIONYSE
Loading
Operating Expenses Over TimeExpanding
Percentile Rank80
3Y CAGR-8.1%
5Y CAGR-6.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-8.1%/yr
vs +13.3%/yr prior
5Y CAGR
-6.6%/yr
Consistent
Acceleration
-21.4pp
Decelerating
Percentile
P80
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $22.74M | +19.7% |
| 2025 | $19.00M | +12.7% |
| 2024 | $16.86M | -42.5% |
| 2023 | $29.34M | +5.6% |
| 2022 | $27.79M | -13.2% |
| 2021 | $32.02M | +114.4% |
| 2020 | $14.94M | -16.1% |
| 2019 | $17.81M | +21.4% |
| 2018 | $14.67M | +0.0% |
| 2017 | $14.67M | - |